Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
07
07
2023
received:
01
06
2023
accepted:
16
07
2023
pubmed:
7
8
2023
medline:
7
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
The current gold standard of response assessment in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) is morphologic complete remission (CR) and CR with incomplete count recovery (CRi), both of which require an invasive BM evaluation. Outside of clinical trials, BM evaluations are only performed in ~50% of patients during follow-up, pinpointing a clinical need for response endpoints that do not necessitate BM assessments. We define and validate a new response type termed "peripheral blood complete remission" (PB-CR) that can be determined from the differential blood count and clinical parameters without necessitating a BM assessment. We compared the predictive value of PB-CR with morphologic CR/CRi in 1441 non-selected, consecutive patients diagnosed with MDS (n = 522; 36.2%), CMML (n = 132; 9.2%), or AML (n = 787; 54.6%), included within the Austrian Myeloid Registry (aMYELOIDr; NCT04438889). Time-to-event analyses were adjusted for 17 covariates remaining in the final Cox proportional hazards (CPH) model. DeepSurv, a CPH neural network model, and permutation-based feature importance were used to validate results. 1441 patients were included. Adjusted median overall survival for patients achieving PB-CR was 22.8 months (95%CI 18.9-26.2) versus 10.4 months (95%CI 9.7-11.2) for those who did not; HR = 0.366 (95%CI 0.303-0.441; p < .0001). Among patients achieving CR, those additionally achieving PB-CR had a median adjusted OS of 32.6 months (95%CI 26.2-49.2) versus 21.7 months (95%CI 16.9-27.7; HR = 0.400 [95%CI 0.190-0.844; p = .0161]) for those who did not. Our deep neural network analysis-based findings from a large, prospective cohort study indicate that BM evaluations solely for the purpose of identifying CR/CRi can be omitted.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1685-1698Informations de copyright
© 2023 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.
Références
Pleyer L, Sekeres MA. An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes. Lancet Haematol. 2022;9(10):e714-e716.
Sekeres MA, Steensma DP. Rethinking clinical trial endpoints in myelodysplastic syndromes. Leukemia. 2019;33(3):570-575.
Kim N, Pavletic S, Norsworthy KJ. Meaningful response criteria for myelodysplastic syndromes. Br J Haematol. 2022;196(5):1137-1148.
Chandhok NS, Sekeres MA. What constitutes meaningful improvement in myelodysplastic syndromes? Leuk Lymphoma. 2022;63:1-8.
Bloomfield CD, Estey E, Pleyer L, et al. Time to repeal and replace response criteria for acute myeloid leukemia? Blood Rev. 2018;32(5):416-425.
Schuh AC, Dohner H, Pleyer L, Seymour JF, Fenaux P, Dombret H. Azacitidine in adult patients with acute myeloid leukemia. Crit Rev Oncol Hematol. 2017;116:159-177.
Pleyer L, Dohner H, Dombret H, et al. Azacitidine for front-line therapy of patients with AML: reproducible efficacy established by direct comparison of international phase 3 trial data with registry data from the Austrian Azacitidine registry of the AGMT study group. Int J Mol Sci. 2017;18(2):415-432.
Schuh ADH, Sandhu I, JSeymour JF, et al. Overall survival (OS) without complete remission (CR) in older patients with acute myeloid leukemia (AML): azacitidine (AZA) vs conventional care regimens (CCR) in the AZA AML-001 study. Haematologica. 2015;100:219-220.
Pleyer L, Burgstaller S, Stauder R, et al. Is it time to redefine response in elderly patients with World Health Organization-defined acute myeloid leukemia unfit for intensive chemotherapy? Blood. 2015;126(23):126.
Pleyer L, Pfeilstoecker M, Stauder R, et al. Expanding on current definitions of hematologic improvement in MDS, CMML and AML: landmark analyses of 1301 patients treated with Azacitidine in the Austrian registry of hypomethylating agents by the AGMT-study group. Blood. 2019;134(Supplement_1):3182.
Pleyer L, Pfeilstocker M, Stauder R, et al. Peripheral blood complete remission provides added value to the classical definition of morphologic complete remission-a prospective cohort study of 1441 patients with MDS, CMML and AML treated within the Austrian Azacitidine registry. Blood. 2021;138:3387.
Pleyer L, Burgstaller S, Girschikofsky M, et al. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine registry of the AGMT-study group. Ann Hematol. 2014;93(11):1825-1838.
Oster HS, Crouch S, Smith A, et al. A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS. Blood Adv. 2021;5(16):3066-3075.
Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200-1228.
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703-1719.
Dohner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-1377.
Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465.
Zeidan AM, Platzbecker U, Bewersdorf JP, et al. Consensus proposal for revised international working group response criteria for higher risk myelodysplastic syndromes. Blood. 2023;141:2047-2061.
Tazi Y, Arango-Ossa JE, Zhou Y, et al. Unified classification and risk-stratification in acute myeloid leukemia. Nat Commun. 2022;13(1):4622.
Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-425.
Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working Group for Diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642-4649.
Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.
Savona MR, Malcovati L, Komrokji R, et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood. 2015;125(12):1857-1865.
Platzbecker U, Fenaux P, Ades L, et al. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. Blood. 2019;133(10):1020-1030.
Jansko-Gadermeir B, Leisch M, Gassner FJ, et al. Myeloid NGS analyses of paired samples from bone marrow and peripheral blood yield concordant results: a prospective cohort analysis of the AGMT study group. Cancers (Basel). 2013;15(8):2305-2325.
Leisch M, Pfeilstocker M, Stauder R, et al. Adverse events in 1406 patients receiving 13,780 cycles of Azacitidine within the Austrian registry of hypomethylating agents-a prospective cohort study of the AGMT study-group. Cancers (Basel). 2022;14(10):2459-2478.
Dinmohamed AG, van Norden Y, Visser O, et al. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry. Leukemia. 2015;29(12):2449-2451.
Dinmohamed AG, van Norden Y, Visser O, et al. The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in The Netherlands. Leuk Res. 2015;39(2):177-182.
Pleyer L, Leisch M, Kourakli A, et al. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Lancet Haematol. 2021;8(2):e135-e148.
Pleyer L, Burgstaller S, Stauder R, et al. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. J Hematol Oncol. 2016;9:39.
Pleyer L, Heibl S, Tinchon C, et al. Health-related quality of life as assessed by the EQ-5D-5L predicts outcomes of patients treated with Azacitidine-a prospective cohort study by the AGMT. Cancers (Basel). 2023;15(5):1388-1408.
Pleyer L, Stauder R, Burgstaller S, et al. Azacitidine in patients with WHO-defined AML-results of 155 patients from the Austrian Azacitidine registry of the AGMT-study group. J Hematol Oncol. 2013;6:32.
Efficace F, Gaidano G, Breccia M, et al. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. Lancet Oncol. 2015;16(15):1506-1514.
Katzman JL, Shaham U, Cloninger A, Bates J, Jiang T, Kluger Y. DeepSurv: personalized treatment recommender system using a cox proportional hazards deep neural network. BMC Med Res Methodol. 2018;18(1):24.
Hatano Y, Ishihara T, Hirokawa S, Onodera O. Machine learning approach for the prediction of age-specific probability of SCA3 and DRPLA by survival curve analysis. Neurol Genet. 2023;9(3):e200075.
Zeng J, Li K, Cao F, Zheng Y. Development and validation of survival prediction model for gastric adenocarcinoma patients using deep learning: a SEER-based study. Front Oncol. 2023;13:1131859.
Wang D, Pan B, Huang JC, et al. Development and validation of machine learning models for predicting prognosis and guiding individualized postoperative chemotherapy: a real-world study of distal cholangiocarcinoma. Front Oncol. 2023;13:1106029.
Li B, Yang L, Jiang C, et al. Integrated multi-dimensional deep neural network model improves prognosis prediction of advanced NSCLC patients receiving bevacizumab. Front Oncol. 2023;13:1052147.
Kim DY, Choi KH, Kim JH, et al. Deep learning-based personalised outcome prediction after acute ischaemic stroke. J Neurol Neurosurg Psychiatry. 2023;94(5):369-378.
Deng Y, Liu L, Jiang H, et al. Comparison of state-of-the-art neural network survival models with the pooled cohort equations for cardiovascular disease risk prediction. BMC Med Res Methodol. 2023;23(1):22.
Yang B, Liu C, Wu R, et al. Development and validation of a DeepSurv nomogram to predict survival outcomes and guide personalized adjuvant chemotherapy in non-small cell lung cancer. Front Oncol. 2022;12:895014.
Huang C, Dai Y, Chen Q, et al. Development and validation of a deep learning model to predict survival of patients with esophageal cancer. Front Oncol. 2022;12:971190.
Bao L, Wang YT, Zhuang JL, et al. Machine learning-based overall survival prediction of elderly patients with multiple myeloma from multicentre real-life data. Front Oncol. 2022;12:922039.
Howard FM, Kochanny S, Koshy M, Spiotto M, Pearson AT. Machine learning-guided adjuvant treatment of Head and neck cancer. JAMA Netw Open. 2020;3(11):e2025881.
She Y, Jin Z, Wu J, et al. Development and validation of a deep learning model for non-small cell lung cancer survival. JAMA Netw Open. 2020;3(6):e205842.
Jobczyk M, Stawiski K, Kaszkowiak M, et al. Deep learning-based recalibration of the CUETO and EORTC prediction tools for recurrence and progression of non-muscle-invasive bladder cancer. Eur Urol Oncol. 2022;5(1):109-112.